Krystal Biotech
NEWS
Results from its GEM-3 trial on VYJUVEK demonstrated statistical significance in its ability to promote complete wound healing within six months compared to a placebo.
Yet another busy week for clinical trial news. Here’s a look.
On the back of a $135 million public offering in February, rare disease gene therapy company Krystal Biotech has launched subsidiary Jeune Inc. to promote its gene therapies for aesthetic skin conditions.
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.
Biopharma and life sciences strengthen their executive leadership teams and boards with this week’s Movers & Shakers.
Krystal Biotech and Foghorn Therapeutics are beginning 2020 with significant expansion projects.
Pharma and life sciences companies strengthen their leadership and boards with this week’s appointments.
Krystal Biotech Inc. announced that Krish S. Krishnan, chairman and chief executive officer, will present at the Piper Jaffray 31st Annual Healthcare Conference in New York City being held Dec. 3-5 in New York.
JOBS
IN THE PRESS